ProMIS Neurosciences develops antibody therapies that target harmful misfolded proteins in neurodegenerative diseases such as Alzheimer's. PMN reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 14 | Guggenheim | Maintained | Buy | |
| Jul 29 | Guggenheim | Maintained | Buy | |
| Jul 28 | Chardan Capital | Target raised | Buy | |
| Jul 27 | Chardan Capital | Initiated | Buy | |
| Jul 8 | Roth Capital | Initiated | Buy |
Seasonality
How PMN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.
Whale Options Flow
90DNo whale options trades in PMN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMN is in one of them and how their past PMN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PMN in an article yet. Here's the latest on the wider market.
About ProMIS Neurosciences
ProMIS Neurosciences is a biotechnology company based in Toronto, Canada, that is developing antibody therapies for neurodegenerative diseases. Its main program targets Alzheimer's disease, and its other candidates address conditions such as ALS and Parkinson's disease. The company uses a computational platform to find targets that appear only on the harmful, misfolded form of a protein, so its antibodies aim to leave the healthy form alone. The therapies are intended for patients with these conditions, and the company is still in clinical development.
- Headquarters
- Toronto, Ontario, Canada